Montreal cancer company Repare inks deal with Roche worth more than US$1B
drug company, which is working on highly-targeted therapies, says Roche will help develop and commercialize the drug camonsertib.for the treatment of tumors.
Repare says under the terms of the licence and collaboration agreement, it will receive a US$125 million upfront payment, and is “eligible to receive up to US$1.2 billion in potential clinical, regulatory, commercial and sales milestones.”
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Montreal cancer drug developer Repare strikes US$1-billion-plus deal with RocheThe deal will see Repare enter into a worldwide license and collaboration agreement with Roche to develop and commercialize the Montreal company’s drug camonsertib, also known as RP-3500
Read more »
Montreal cancer drug developer Repare strikes US$1-billion-plus deal with RocheThe deal will see Repare enter into a worldwide license and collaboration agreement with Roche to develop and commercialize the Montreal company’s drug camonsertib, also known as RP-3500
Read more »
Montreal’s Bennedict Mathurin ready to make his NBA dreams come true - Montreal | Globalnews.caMontreal basketball player Bennedict Mathurin decided to take a risk and join the NBA Academy Latin America, becoming the first Canadian to do so. His gamble has paid off.
Read more »